Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Nonmalignant Pain
Status:
Completed
Trial end date:
2001-07-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to demonstrate the effectiveness and tolerability of the
buprenorphine transdermal system (5, 10 and 20) in comparison to matching placebo transdermal
system in subjects with chronic nonmalignant pain syndromes currently controlled by oral
opioids. The double-blind treatment intervention duration is 2 weeks during which time
supplemental analgesic medication (acetaminophen) will be provided to all subjects in
addition to study drug.